Regeneron Accounts Payable vs Property Plant and Equipment Net Analysis

REGN Stock

USD 898.56 6.14 0.68%

Regeneron Pharmaceuticals financial indicator trend analysis is much more than just breaking down Regeneron Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Regeneron Pharmaceuticals is a good investment. Please check the relationship between Regeneron Pharmaceuticals Accounts Payable and its Property Plant And Equipment Net accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regeneron Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.

To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.

Accounts Payable vs Property Plant And Equipment Net

Accounts Payable vs Property Plant and Equipment Net Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Regeneron Pharmaceuticals Accounts Payable account and Property Plant and Equipment Net. At this time, the significance of the direction appears to have almost identical trend.

The correlation between Regeneron Pharmaceuticals' Accounts Payable and Property Plant and Equipment Net is 0.95. Overlapping area represents the amount of variation of Accounts Payable that can explain the historical movement of Property Plant and Equipment Net in the same time period over historical financial statements of Regeneron Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Regeneron Pharmaceuticals' Accounts Payable and Property Plant and Equipment Net is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Accounts Payable of Regeneron Pharmaceuticals are associated (or correlated) with its Property Plant and Equipment Net. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Property Plant and Equipment Net has no effect on the direction of Accounts Payable i.e., Regeneron Pharmaceuticals' Accounts Payable and Property Plant and Equipment Net go up and down completely randomly.

Correlation Coefficient

0.95

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Accounts Payable

An accounting item on the balance sheet that represents Regeneron Pharmaceuticals obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Regeneron Pharmaceuticals are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Property Plant And Equipment Net

The total value of a company's physical assets (such as land, buildings, and equipment) used in operations, net of depreciation. It reflects the company's investment in assets used for production.

Most indicators from Regeneron Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Regeneron Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regeneron Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.

To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.At this time, Regeneron Pharmaceuticals' Selling General Administrative is very stable compared to the past year. As of the 15th of April 2024, Tax Provision is likely to grow to about 584.1 M, while Sales General And Administrative To Revenue is likely to drop 0.26.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	4.7B	5.6B	7.1B	7.4B
Cost Of Revenue	2.4B	1.6B	883.7M	927.9M

Total Operating Expenses Cost Of Revenue

Regeneron Pharmaceuticals fundamental ratios Correlations

	Total Assets	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Intangible Assets	Short Long Term Debt Total	Other Current Liab	Accounts Payable	Short Term Debt	Property Plant And Equipment Gross	Short Term Investments	Inventory	Other Liab
Total Assets		0.97	1.0	0.94	-0.06	0.99	0.97	0.93	-0.24	0.96	0.98	0.15	0.95	0.32	-0.66	0.97	0.98	0.83	0.93	0.94	0.98	0.58	0.99	0.93	0.98	0.58
Total Current Liabilities	0.97		0.96	0.94	-0.03	0.95	0.99	0.84	-0.31	0.98	0.98	0.2	0.95	0.45	-0.66	0.99	0.99	0.73	0.96	0.88	0.99	0.65	0.97	0.83	0.98	0.56
Total Stockholder Equity	1.0	0.96		0.93	-0.09	0.99	0.95	0.94	-0.25	0.95	0.96	0.13	0.92	0.28	-0.67	0.95	0.97	0.85	0.91	0.96	0.96	0.55	0.99	0.94	0.97	0.56
Property Plant And Equipment Net	0.94	0.94	0.93		-0.16	0.89	0.93	0.87	-0.15	0.91	0.94	0.31	0.96	0.37	-0.44	0.96	0.93	0.68	0.86	0.83	0.95	0.67	0.97	0.81	0.96	0.78
Net Debt	-0.06	-0.03	-0.09	-0.16		0.0	-0.1	-0.01	0.13	-0.14	-0.01	-0.17	0.08	-0.04	-0.49	0.02	-0.09	0.03	0.22	-0.16	-0.08	-0.04	-0.1	0.01	-0.06	-0.4
Retained Earnings	0.99	0.95	0.99	0.89	0.0		0.94	0.93	-0.26	0.95	0.96	0.05	0.91	0.27	-0.75	0.95	0.97	0.87	0.93	0.96	0.95	0.53	0.97	0.95	0.96	0.48
Cash	0.97	0.99	0.95	0.93	-0.1	0.94		0.82	-0.3	0.98	0.98	0.23	0.93	0.45	-0.62	0.98	0.99	0.71	0.95	0.88	0.98	0.63	0.95	0.82	0.97	0.54
Non Current Assets Total	0.93	0.84	0.94	0.87	-0.01	0.93	0.82		-0.07	0.8	0.86	0.07	0.88	0.14	-0.62	0.87	0.84	0.9	0.8	0.91	0.86	0.48	0.93	0.98	0.89	0.6
Non Currrent Assets Other	-0.24	-0.31	-0.25	-0.15	0.13	-0.26	-0.3	-0.07		-0.39	-0.2	-0.05	-0.06	-0.37	0.26	-0.19	-0.32	-0.4	-0.26	-0.26	-0.22	0.01	-0.22	-0.15	-0.23	-0.01
Cash And Short Term Investments	0.96	0.98	0.95	0.91	-0.14	0.95	0.98	0.8	-0.39		0.97	0.18	0.89	0.41	-0.63	0.95	0.99	0.73	0.92	0.91	0.97	0.58	0.95	0.82	0.95	0.5
Net Receivables	0.98	0.98	0.96	0.94	-0.01	0.96	0.98	0.86	-0.2	0.97		0.22	0.97	0.33	-0.65	0.99	0.99	0.71	0.96	0.89	0.98	0.62	0.97	0.85	0.97	0.56
Common Stock Shares Outstanding	0.15	0.2	0.13	0.31	-0.17	0.05	0.23	0.07	-0.05	0.18	0.22		0.28	0.27	0.37	0.24	0.19	-0.07	0.17	0.05	0.21	0.23	0.2	-0.02	0.16	0.47
Non Current Liabilities Total	0.95	0.95	0.92	0.96	0.08	0.91	0.93	0.88	-0.06	0.89	0.97	0.28		0.37	-0.59	0.99	0.93	0.67	0.94	0.81	0.96	0.69	0.95	0.83	0.96	0.65
Other Current Assets	0.32	0.45	0.28	0.37	-0.04	0.27	0.45	0.14	-0.37	0.41	0.33	0.27	0.37		-0.13	0.42	0.39	0.12	0.43	0.14	0.45	0.69	0.29	0.12	0.43	0.24
Other Stockholder Equity	-0.66	-0.66	-0.67	-0.44	-0.49	-0.75	-0.62	-0.62	0.26	-0.63	-0.65	0.37	-0.59	-0.13		-0.63	-0.65	-0.71	-0.76	-0.66	-0.61	-0.25	-0.6	-0.71	-0.63	0.11
Total Liab	0.97	0.99	0.95	0.96	0.02	0.95	0.98	0.87	-0.19	0.95	0.99	0.24	0.99	0.42	-0.63		0.97	0.71	0.96	0.86	0.99	0.68	0.97	0.84	0.98	0.61
Total Current Assets	0.98	0.99	0.97	0.93	-0.09	0.97	0.99	0.84	-0.32	0.99	0.99	0.19	0.93	0.39	-0.65	0.97		0.75	0.94	0.91	0.98	0.61	0.97	0.85	0.97	0.53
Intangible Assets	0.83	0.73	0.85	0.68	0.03	0.87	0.71	0.9	-0.4	0.73	0.71	-0.07	0.67	0.12	-0.71	0.71	0.75		0.71	0.87	0.72	0.28	0.81	0.94	0.77	0.37
Short Long Term Debt Total	0.93	0.96	0.91	0.86	0.22	0.93	0.95	0.8	-0.26	0.92	0.96	0.17	0.94	0.43	-0.76	0.96	0.94	0.71		0.81	0.94	0.61	0.91	0.81	0.94	0.4
Other Current Liab	0.94	0.88	0.96	0.83	-0.16	0.96	0.88	0.91	-0.26	0.91	0.89	0.05	0.81	0.14	-0.66	0.86	0.91	0.87	0.81		0.87	0.36	0.93	0.94	0.88	0.47
Accounts Payable	0.98	0.99	0.96	0.95	-0.08	0.95	0.98	0.86	-0.22	0.97	0.98	0.21	0.96	0.45	-0.61	0.99	0.98	0.72	0.94	0.87		0.73	0.97	0.84	0.99	0.59
Short Term Debt	0.58	0.65	0.55	0.67	-0.04	0.53	0.63	0.48	0.01	0.58	0.62	0.23	0.69	0.69	-0.25	0.68	0.61	0.28	0.61	0.36	0.73		0.57	0.41	0.67	0.49
Property Plant And Equipment Gross	0.99	0.97	0.99	0.97	-0.1	0.97	0.95	0.93	-0.22	0.95	0.97	0.2	0.95	0.29	-0.6	0.97	0.97	0.81	0.91	0.93	0.97	0.57		0.91	0.97	0.65
Short Term Investments	0.93	0.83	0.94	0.81	0.01	0.95	0.82	0.98	-0.15	0.82	0.85	-0.02	0.83	0.12	-0.71	0.84	0.85	0.94	0.81	0.94	0.84	0.41	0.91		0.88	0.47
Inventory	0.98	0.98	0.97	0.96	-0.06	0.96	0.97	0.89	-0.23	0.95	0.97	0.16	0.96	0.43	-0.63	0.98	0.97	0.77	0.94	0.88	0.99	0.67	0.97	0.88		0.6
Other Liab	0.58	0.56	0.56	0.78	-0.4	0.48	0.54	0.6	-0.01	0.5	0.56	0.47	0.65	0.24	0.11	0.61	0.53	0.37	0.4	0.47	0.59	0.49	0.65	0.47	0.6

Click cells to compare fundamentals

Regeneron Pharmaceuticals Account Relationship Matchups

Regeneron Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	14.8B	17.2B	25.4B	29.2B	33.1B	34.7B
Total Current Liabilities	1.8B	2.8B	3.5B	3.8B	3.4B	3.6B
Total Stockholder Equity	11.1B	11.0B	18.8B	22.7B	26.0B	27.3B
Property Plant And Equipment Net	2.9B	3.2B	3.5B	3.8B	4.1B	4.4B
Net Debt	(903.9M)	502M	(185.9M)	(404.5M)	(27.1M)	(28.5M)
Retained Earnings	7.4B	10.9B	19.0B	23.3B	27.3B	28.6B
Cash	1.6B	2.2B	2.9B	3.1B	2.7B	2.9B
Non Current Assets Total	4.2B	4.4B	4.9B	7.1B	13.6B	14.3B
Non Currrent Assets Other	531.8M	328.9M	555.2M	(4.7B)	444.1M	466.3M
Cash And Short Term Investments	6.5B	6.7B	12.5B	14.3B	10.8B	11.4B
Net Receivables	2.7B	4.1B	6.0B	5.3B	5.7B	6.0B
Common Stock Shares Outstanding	114.6M	115.1M	112.2M	113.5M	113.7M	75.4M
Liabilities And Stockholders Equity	14.8B	17.2B	25.4B	29.2B	33.1B	34.7B
Non Current Liabilities Total	1.9B	3.3B	3.2B	2.7B	3.7B	3.9B
Other Current Assets	959.3M	1.2B	332.4M	933M	386.6M	203.9M
Other Stockholder Equity	3.7B	102.9M	(173.4M)	(404M)	(1.2B)	(1.1B)
Total Liab	3.7B	6.1B	6.7B	6.6B	7.1B	7.5B
Total Current Assets	10.6B	12.8B	20.5B	22.1B	19.5B	20.5B
Short Long Term Debt Total	713.9M	2.7B	2.7B	2.7B	2.7B	2.8B
Other Current Liab	781.1M	122.4M	1.7B	2.0B	2.4B	2.5B
Accounts Payable	418.1M	475.5M	564M	589.2M	606.6M	636.9M
Property Plant And Equipment Gross	2.9B	3.2B	4.9B	5.4B	6.1B	6.4B
Accumulated Other Comprehensive Income	21.1M	29.3M	(26.2M)	(238.8M)	(80.9M)	(76.9M)
Short Term Investments	1.6B	1.4B	2.8B	4.6B	8.1B	8.5B
Inventory	1.4B	1.9B	2.0B	2.4B	2.6B	2.7B
Other Liab	889M	635.5M	515.3M	707.8M	814.0M	854.7M
Other Assets	913.3M	2.8B	555.2M	747.6M	859.7M	902.7M
Property Plant Equipment	2.9B	3.2B	3.5B	3.8B	4.3B	4.5B
Current Deferred Revenue	591.7M	577.7M	442M	547.7M	458.9M	481.8M
Net Tangible Assets	11.1B	11.0B	18.8B	21.7B	25.0B	26.3B
Retained Earnings Total Equity	7.4B	10.9B	19.0B	23.3B	26.8B	28.1B
Long Term Debt Total	713.9M	2.0B	2.0B	2.0B	2.3B	2.4B
Capital Surpluse	4.4B	6.7B	8.1B	9.9B	11.4B	12.0B
Long Term Investments	3.3B	3.1B	6.8B	6.6B	5.4B	3.3B

Currently Active Assets on Macroaxis

LTC	Litecoin
STETH	Staked Ether
LINK	Chainlink
XLM	Stellar
CRO	Cronos

When determining whether Regeneron Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Regeneron Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Regeneron Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Regeneron Pharmaceuticals Stock:

How To Invest In Regeneron

Details

Is Regeneron Stock a good investment?

Details

What is Regeneron Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regeneron Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.

To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.

Note that the Regeneron Pharmaceuticals information on this page should be used as a complementary analysis to other Regeneron Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.

Complementary Tools for Regeneron Stock analysis

When running Regeneron Pharmaceuticals' price analysis, check to measure Regeneron Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regeneron Pharmaceuticals is operating at the current time. Most of Regeneron Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Regeneron Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regeneron Pharmaceuticals' price. Additionally, you may evaluate how the addition of Regeneron Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

	CEOs Directory Screen CEOs from public companies around the world
	Equity Valuation Check real value of public entities based on technical and fundamental data
	Analyst Advice Analyst recommendations and target price estimates broken down by several categories
	My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
	Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk
	Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios
	ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
	Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
	Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities
	Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
	Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios
	Volatility Analysis Get historical volatility and risk analysis based on latest market data
	Risk-Return Analysis View associations between returns expected from investment and the risk you assume

Is Regeneron Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regeneron Pharmaceuticals. If investors know Regeneron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regeneron Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.03)

Earnings Share

34.74

Revenue Per Share

122.935

Quarterly Revenue Growth

0.006

Return On Assets

0.0849

The market value of Regeneron Pharmaceuticals is measured differently than its book value, which is the value of Regeneron that is recorded on the company's balance sheet. Investors also form their own opinion of Regeneron Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Regeneron Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regeneron Pharmaceuticals' market value can be influenced by many factors that don't directly affect Regeneron Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Regeneron Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Regeneron Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regeneron Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Regeneron Accounts Payable vs Property Plant and Equipment Net Analysis

Accounts Payable vs Property Plant And Equipment Net

Accounts Payable vs Property Plant and Equipment Net Correlation Analysis

Correlation Coefficient

Accounts Payable

Property Plant And Equipment Net

Regeneron Pharmaceuticals fundamental ratios Correlations

Regeneron Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Regeneron Pharmaceuticals fundamental ratios Accounts

Currently Active Assets on Macroaxis

Complementary Tools for Regeneron Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Retained Earnings	+ 0.99	Total Assets
Property Plant And Equipment Gross	+ 0.99	Total Assets
Cash	+ 0.99	Total Current Liabilities
Total Liab	+ 0.99	Total Current Liabilities
Total Current Assets	+ 0.99	Total Current Liabilities

Short Long Term Debt Total	- 0.76	Other Stockholder Equity
Other Stockholder Equity	- 0.75	Retained Earnings
Short Term Investments	- 0.71	Other Stockholder Equity
Intangible Assets	- 0.71	Other Stockholder Equity
Other Stockholder Equity	- 0.67	Total Stockholder Equity
Other Current Liab	- 0.66	Other Stockholder Equity